Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine as Prolonged Adjuvant Treatment for Breast Cancer
NCT02842099Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2014
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02842099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842099.